jRCTs041200107招募中不适用
The effects of dapagliflozin on anemia of chronic kidney disease (Study A)
未提供0 个研究点目标入组 96 人开始时间: 2021年4月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 96
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Those with CKD stage 3-4 and diabetes mellitus or heart failure with reduced ejection fraction, those with CKD without diabetes or heart failure with reduced ejection fration (eGFR 15-59 mL/min/1.73m2)
- •(2) Those on erythropoiesis stimulating agents (ESA) or hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors
- •(3) Those without iron deficiency (transferrin saturation >= 20% or ferritin >= 50 ng/mL)
- •(4) Those who are not on SGLT2 inhibitors
- •(5) Those who gave informed consent
- •(6) Age >= 20 years old at the time of consent (both men and women, and inpatients and outpatients)
- •(7) For those with heart failure with reduced ejection fraction, they should be on standard therapy for heart failure (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or beta blockers)
排除标准
- •(1) Those with history of allergy to dapagliflozin
- •(2) Those with severe ketoacidosis, hyperosmolar coma or precoma, or type 1 diabetes
- •(3) Those with hospitalization due to infection, surgery under general anesthesia, trauma requiring surgical intervention, gastrointestinal bleeding, transfusion, active malignancy within 3 months, or those expecting surgery within 3 months
- •(4) Those with non-adherence
- •(5) Pregnant or potentially pregnant women
- •(6) Those whom treating physicians judge inappropriate candidates for participating in the study
结局指标
主要结局
-
The change in dose of ESA/HIF-PH inhibitors
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
The effects of dapagliflozin on anemia of chronic kidney disease (Study B)Chronic kidney disease stage 3-4 with anemia of chronic kidney diseaseDapagliflozin, diabetes mellitus, chronic kidney disease, anemia of chronic kidney disease, heart failure with reduced ejection fractionJPRN-jRCTs041200108Hamano Takayuki96
招募中
不适用
The effects of dapagliflozin on anemia of chronic kidney disease (Study B)Chronic kidney disease stage 3-4 with anemia of chronic kidney diseasejRCTs04120010896
招募中
不适用
The effects of dapagliflozin on anemia of chronic kidney disease (Study A)Chronic kidney disease stage 3-4 and anemia of chronic kidney diseaseDapagliflozin, diabetes mellitus, chronic kidney disease Anemia of chronic kidney disease, heart failure with reduced ejection fractionJPRN-jRCTs041200107Hamano Takayuki96
进行中（未招募）
1 期
Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory studyPatients with T2DM and hypertension aged 40 to 70 years (including)EUCTR2017-004889-10-DEniversity Hospital Tuebingen75
招募中
3 期
Effect of Dapagliflozin in The Prevention of Iodinated Contrast Media Induced Acute Kidney InjuryAcute kidney injury caused by iodinated contrast agents.Acute kidney failureIRCT20170609034406N11Tabriz University of Medical Sciences80